The WID®-easy test - a rapid, accurate, and simple triage tool for peri- and post-menopausal women experiencing abnormal uterine bleeding - has officially launched in the UK. The minimally invasive, epigenetic test is poised to significantly improve diagnostic accuracy while reducing the number of further investigative procedures, such as hysteroscopy and curettage by >90% 1.
The WID-easy test was developed by academics from University College London and University of Innsbruck in partnership with The Eve Appeal, the UK’s largest gynaecological cancer charity. Prof. Martin Widschwendter, inventor of the WID-easy test, shared:
“The WID-easy test represents years of dedicated research by a committed team. We are proud to have developed a test that addresses an urgent gap in women’s health and performs well across all women."
A revolution for the Endometrial Cancer Diagnostic Pathway
Every year in the UK, 275,000 women experience AUB. ~95,000 will have a thickened endometrium ( ≥ 4mm) but less than 10,000 will have endometrial cancer 2. This obstructs the pathway for those who need urgent treatment, with clinicians performing thousands of invasive procedures on those who don’t need them.
The WID-easy test is characterised by extremely high values for sensitivity (90.9%), specificity (97.3%) and Negative Predictive Value (99.7%). Above all, the WID-easy test Positive Predictive Value is 6 times higher than that of sonography* (50% vs. 8.7%) 1. WID-easy has been evaluated in multiple peer-reviewed studies and consistently demonstrates excellent accuracy 1,3-6.
This means WID-easy can reduce the number of unnecessary procedures by 90% while detecting the same number of cancers as transvaginal ultrasound, making the treatment pathway shorter, less invasive, with better patient outcomes for those with and without cancer.
Implementation in the UK
Already introduced in other European countries such as Switzerland, Austria, and Germany where it has been met with enthusiasm, the WID-easy test has shown significant potential to address the problems faced by patients and clinics with the rising incidence of endometrial cancer.
With its launch in the UK, WID-easy is expected to transform the diagnostic pathway, with the potential to reduce costs to the NHS via the significant reduction in unnecessary gynaecological procedures 1.
For more information, book a meeting with a WID-easy expert here.
References:
Evans et al., 2023 - EPI-SURE.
Cancer research UK report, 2023
Chiara Herzog et al. 2023
Schreiberhuber et al. 2023
Illah et al. 2024
Ken-Amoah et al., IJC, 2024
*PPV of sonography based on endometrial thickness cutoff of ≥ 4mm≥
Comments